Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
˗ PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) … [Read more…]
